In today’s world, data is king. At Neurocern, we process millions of data fields to find clinical insights. For Medicare supplement data, that means improving risk adjustment accuracy and quality of care. Neurological diseases are the leading cause of disability globally, the second leading cause of death, and a top three condition in health mortality assumptions. As a result, there is a trickle down impact in underwriting, latent mortality risk, and reserving for Medicare supplement products.
With the new approval of Biogen’s Aducanumab, insurers will face even more pressure to be able to predict the future utilization risk and model costs accurately for disease modifying treatments. In one New York Times article, it was demonstrated that costs related to Alzheimer’s drugs, like Aducanumab, could match that of NASA spending, with estimates reaching $29B. With half of cognitive impairment cases undiagnosed, this translates to unaccounted risk.
At Neurocern, we deploy our expert system — trained with millions of clinical and claims data points and years worth of research reference data — to help financial services and insurance organizations leverage AI-driven analytics and deep learning protocols to create actionable insights for underwriting, claims, and risk management. To see how Neurocern can empower your organization, schedule a demo with our team today.
To learn more, tune in on Wednesday, September 9th, 2021 to hear from our CEO and Founder, Dr. Anitha Rao at the 2021 Medicare Supplement Conference in Chicago, Illinois.